José Baselga
Spanish oncologist (1959–2021) / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about José Baselga?
Summarize this article for a 10 year old
Josep Baselga i Torres, known in Spanish as José Baselga (3 July 1959 – 21 March 2021), was a Spanish medical oncologist and researcher focused on the development of novel molecular targeted agents, with a special emphasis in breast cancer. Through his career he was associated with the Memorial Sloan Kettering Cancer Center, Vall d'Hebron Institute of Oncology, and the Massachusetts General Hospital in their hematology and oncology divisions. He led the development of the breast cancer treatment Herceptin, a monoclonal antibody, that targets the HER2 protein, which is impacted in aggressive breast cancers.
José Baselga | |
---|---|
Born | (1959-07-03)3 July 1959 |
Died | 21 March 2021(2021-03-21) (aged 61) Cerdanya, Catalonia, Spain |
Nationality (legal) | Spanish |
Alma mater | |
Scientific career | |
Fields | Oncology |
Institutions | |
He served as Physician-in-Chief at the Memorial Sloan Kettering Cancer Center and was also the president of the American Association for Cancer Research.[1][2][3][4]